Home Biosimilar Antibodies Immunology & Inflammation Interleukins inhibitor Secukinumab (anti-IL-17A)
For research use only. Not for use in humans.

Secukinumab (anti-IL-17A)

Synonyms: AIN457

Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.

Secukinumab (anti-IL-17A)

Click to purchase the isotype control of Secukinumab (anti-IL-17A)

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A202501 Purity: 99.82% Protein concentration: 5.00mg/ml Endotoxin Level: <1EU/mg
99.82

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 0
JTE-607 Dihydrochloride 0 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 3 PIKfyve
MD2-TLR4-IN-1 0 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 63 TLR4,NO,TNF-α
Apilimod 18 PIKfyve
LMT-28 0
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 4
Diethyl phosphate 0
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 1 iNOS,TNF-α,PGE2
PKR-IN-C16 7 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 0 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 22 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 0 TNFα,MCP-1/CCL2,NOX2
AUDA 0 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 1 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 0 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 13
Methylthiouracil 0 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.
In vitro

Secukinumab can reduce cell growth in the miR130b-knockdown OCI-ly10 co-culture system.
Cell Research

MTT assay was adopted to measure cell growth in the control inhibitor or miR130b inhibitor transfected OCI-ly10 co-culture system upon treatment with or without IL17 inhibitor.
In vivo

Secukinumab administration significantly attenuates AAV8-IRF8 mediated recruitment of neutrophils, also downregulates the autophagy level and inhibits the release of either autophagy-dependent or independent chemokines in vivo.
Animal Research

Animal Models: C57BL/6 mice, IRF8 FLOX mice (C57BL/6J background)
Dosages: 200 μg
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/34400126/
 
References

Product Details

CAS No. 1229022-83-6
Isotype Human IgG1
Source Human
Sterility 0.2 μM filtered
Formulation PBS buffer, pH 7.2
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.